Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seretide versus fluticasone for inhaled corticosteroid down-titration in asthma
ACTRN12605000465651Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2002
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of salmeterol + fluticasone, fluticasone propionate and salmeterol in asthma, sponsored by GSK. Primary endpoint: Average daily fluticasone propionate dose. Started Mar 2002; status: active, not recruiting.
02
Drugs
salmeterol + fluticasonefluticasone propionatesalmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12605000465651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000465651.